TCGA-D8-A13Z-01A-11R-A115-07
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
- overall_survival_months
- 21
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.500
- INTERFERON_GAMMA_RESPONSE+0.470
- E2F_TARGETS+0.450
- MTORC1_SIGNALING+0.440
- G2M_CHECKPOINT+0.430
- IL6_JAK_STAT3_SIGNALING+0.410
- MITOTIC_SPINDLE+0.410
- INFLAMMATORY_RESPONSE+0.390
- CHOLESTEROL_HOMEOSTASIS+0.380
- GLYCOLYSIS+0.380
Top 10 suppressed
- ESTROGEN_RESPONSE_EARLY-0.360
- PANCREAS_BETA_CELLS-0.250
- ESTROGEN_RESPONSE_LATE-0.200
- ADIPOGENESIS-0.160
- BILE_ACID_METABOLISM-0.120
- OXIDATIVE_PHOSPHORYLATION-0.120
- MYOGENESIS-0.110
- PEROXISOME-0.060
- DNA_REPAIR-0.020
- FATTY_ACID_METABOLISM-0.010
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A2-A1G1-01A-21R-A13Q-07 | — | E | 0.888 |
| 2 | TCGA-E2-A150-01A-11R-A12D-07 | — | E | 0.883 |
| 3 | TCGA-BH-A0B3-01A-11R-A056-07 | — | E | 0.853 |
| 4 | TCGA-A8-A08R-01A-11R-A034-07 | — | E | 0.842 |
| 5 | TCGA-D8-A1JL-01A-11R-A13Q-07 | — | D | 0.835 |
| 6 | SRR35579823 | — | D | 0.835 |
| 7 | TCGA-EW-A1P4-01A-21R-A144-07 | — | E | 0.833 |
| 8 | TCGA-D8-A1XQ-01A-11R-A14M-07 | — | E | 0.832 |
| 9 | TCGA-XF-A9SY-01A-21R-A42T-07 | — | — | 0.830 |
| 10 | 20050099.TNBC | — | D | 0.830 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.500 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.470 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.450 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.440 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.430 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.410 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.410 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.390 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.380 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.380 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.340 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.340 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.340 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.330 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.330 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.300 | Inavolisib | — uncovered |
| HYPOXIA | 0.270 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.260 | Inavolisib | — uncovered |
| COAGULATION | 0.250 | Binimetinib | — uncovered |
| NOTCH_SIGNALING | 0.250 | Inavolisib | — uncovered |